Major depressive disorder is not considered curable in the traditional medical sense, but it is highly treatable, and many people reach a point where they have no symptoms at all. The distinction matters: psychiatry uses the term “remission” rather than “cure” because depression can return, but remission can last years or even a lifetime for some people. Whether that feels like a cure in practice depends on the individual.
Why Psychiatry Says “Remission,” Not “Cure”
The DSM-5, the standard diagnostic manual in mental health, never uses the word “cure” for depression. Instead, it describes two levels of improvement. Partial remission means symptoms are still present but no longer meet the full criteria for a depressive episode. Full remission means a person has gone at least two months with no significant signs or symptoms of the disorder. On a standard screening tool like the PHQ-9, that translates to a score below 5 out of 27.
This language is borrowed from oncology, where “remission” signals that a disease has retreated but could potentially return. Some mental health professionals have criticized this framing, arguing that it traps people in an identity as permanently ill. The National Alliance on Mental Illness, for instance, defines depression as “a life-long condition in which periods of wellness alternate with recurrences of illness.” That may be statistically accurate for large populations, but it does not describe every individual’s experience. Some people have a single episode, receive treatment, and never experience depression again.
What the Relapse Numbers Actually Show
The reason clinicians avoid the word “cure” comes down to recurrence rates. Without continued treatment after a first episode, roughly 50% of people relapse within six months of reaching remission. Over a decade, recurrence rates climb above 85% for those who don’t stay on some form of ongoing care. These are sobering numbers, but they come with important context.
With continued treatment, the picture improves significantly. In controlled trials, relapse rates averaged about 23% over roughly eight months, and recurrence rates ranged from 25% to 37% over two years. That means the majority of people who stay engaged with treatment remain well. The gap between treated and untreated recurrence is one of the strongest arguments for not stopping treatment too early, even when you feel better.
About 10 to 30% of people with major depression develop a chronic course, meaning they meet criteria for a depressive episode continuously for two or more years despite adequate treatment. This is a real subset of patients, but it is the minority. The lifetime prevalence of this chronic form is around 3%, compared to 13% for major depression overall.
How Effective Current Treatments Are
The largest real-world trial of antidepressant treatment, known as STAR*D, followed over 3,000 patients through up to four rounds of medication changes. A 2023 reanalysis using the study’s original measurement criteria found that about 25.5% of patients achieved remission on their first medication. Each subsequent switch yielded lower rates: 21% on the second try, 13% on the third, and 10% on the fourth. The cumulative remission rate after all four steps was 35%.
Those numbers reflect medication alone in a real-world clinical population, many of whom had other complicating health conditions. Therapy changes the equation. In one trial comparing cognitive behavioral therapy (CBT) to medication in patients with moderate depression, remission rates at 12 months were 57% for CBT and 51% for medication, both substantially higher than the 37% seen in patients receiving usual care alone. For people with more severe depression, CBT still produced remission in about 31% at 12 months, while medication alone in that severe group was far less effective on its own.
Newer treatments have expanded the options for people who don’t respond to standard approaches. Transcranial magnetic stimulation, a non-invasive procedure that uses magnetic pulses to stimulate brain activity, shows efficacy rates between 30% and 90% in treatment-resistant cases depending on the protocol. Ketamine-based treatments can be effective in up to 70% of patients who haven’t responded to other medications. When TMS and ketamine are combined, studies have found response rates around 80% and remission rates near 43%.
What Happens in the Brain During Recovery
Depression is not just a chemical imbalance that gets corrected like filling a tank. It involves structural changes in the brain, particularly in areas responsible for memory, emotional regulation, and decision-making. These regions can physically shrink during prolonged depression.
The encouraging finding is that treatment can reverse some of these changes. Antidepressant medications have been shown to increase the thickness of the brain’s outer layer within the first week of treatment, a change that predicted better outcomes two months later. Magnetic stimulation therapy has been linked to increases in hippocampal volume, the brain region most associated with memory and learning, along with measurable cognitive improvement. The brain’s ability to reorganize and rebuild neural connections, known as neuroplasticity, appears to be a core mechanism through which multiple types of treatment work.
Exercise as a Treatment, Not Just a Suggestion
Exercise is often mentioned as a lifestyle tip for depression, but the evidence behind it is stronger than most people realize. A meta-analysis of 41 studies found that exercise interventions produced large effects on depressive symptoms. For people specifically diagnosed with major depressive disorder, the “number needed to treat” was 1.9, meaning that for roughly every two people who exercise as part of their treatment, one achieves a meaningful clinical improvement. That is comparable to, and in some analyses better than, the number needed to treat for antidepressant medications. Even when the analysis was restricted to only the most rigorous, low-bias studies, the effects remained moderate to large.
This does not mean exercise replaces medication or therapy for everyone. But it does mean that regular physical activity is a genuinely effective component of treatment, not a soft recommendation.
How Long Treatment Should Continue
One of the most common mistakes is stopping treatment too soon. Clinical guidelines recommend that after reaching remission, patients should continue the same dose of antidepressant medication for at least 16 to 24 weeks, bringing the total treatment period to roughly 6 to 9 months from when treatment began. This continuation phase is specifically designed to prevent relapse during the vulnerable window after symptoms resolve.
For people with recurrent episodes, a history of severe depression, or other risk factors, longer-term maintenance treatment is often recommended. The decision about how long to continue is individual, but the data clearly shows that stopping too early dramatically increases the chance of relapse. After the continuation phase, if someone has remained stable and doesn’t have risk factors for recurrence, gradual discontinuation can be considered.
What “Curable” Means in Practice
If you define “curable” as a guarantee that depression will never return, then no, major depressive disorder is not curable by current medical standards. But if you define it as the ability to live without symptoms, function fully, and feel like yourself again, that outcome is achievable for the majority of people who receive appropriate treatment. Somewhere between 50% and 60% of people reach full remission with first-line treatments, and newer options continue to expand what’s possible for those who don’t respond initially.
The honest answer is that depression sits in the same category as conditions like asthma or high blood pressure: manageable, often to the point of being functionally invisible, but requiring ongoing awareness. Some people will need long-term treatment. Others will have a single episode, recover, and never look back. The trajectory varies enormously from person to person, and the language of “remission” versus “cure” captures a statistical reality about populations, not a predetermined fate for any individual.